
The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.
Hematologist/oncologist at Mayo Clinic
The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.
The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.
The hematologist/oncologist from Mayo Clinic discussed the growing presence of CAR T-cell therapies in lung cancer and melanoma.
The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in common cancers and its use as a biomarker.
The hematologist/oncologist from Mayo Clinic discussed the BASECAMP study and how it will inform future studies assessing Tmod technology.
The hematologist/oncologist from Mayo Clinic discussed the role of HLA loss in a variety of cancers.
Published: January 17th 2022 | Updated:
Published: January 8th 2022 | Updated:
Published: December 9th 2021 | Updated: